ScripPrilenia Therapeutics has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of its neurodegenerative disease drug pridopidine in Europe a
ScripThe failure of FibroGen, Inc. ’s Phase III MATTERHORN trial of roxadustat in anemia among patients with transfusion-dependent lower-risk myelodysplastic syndrome (MDS) likely seals the drug’s fate in
ScripScrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie Continues Development Of Novel S
ScripCatalonia’s biotech sector has continued to boom despite the political storms that struck the region and the rest of Spain just over a year ago and foreign and domestic investment is on the rise. Bioc